KCM
NVAX icon

Kennedy Capital Management’s Novavax NVAX Stock Holding History

Kennedy Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,495
Closed -$7.16M – 660
2021
Q1 		$7.16M Buy
+39,495
New +$7.87M 0.14% 265

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Kennedy Capital Management's NVAX Position: Q2 2021 in Review

Kennedy Capital Management sold out of Novavax (NVAX) in Q2 2021, closing a stake of 39,495 shares — an estimated $7.16M sold.

Kennedy Capital Management first reported a position in NVAX in Q1 2021 and held it in 1 quarter. The position peaked at $7.16M in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Kennedy Capital Management reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Kennedy Capital Management sold 39,495 Novavax shares in Q2 2021, an estimated $7.16M.
  • Kennedy Capital Management first reported a position in Novavax in Q1 2021 and held it in 1 quarter.
  • Kennedy Capital Management's Novavax position peaked at $7.16M in Q1 2021.
  • 407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Kennedy Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.